Health product recall

JAMP ATORVASTATIN CALCIUM: Affected lot may be labelled with the incorrect strength on the label.

Last updated

Summary

Product
JAMP ATORVASTATIN CALCIUM
Issue
Health products - Dosage
Health products - Labelling
What to do

Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. If you are unsure, contact your pharmacist to check if your bottle contains the correct tablets. If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Seek immediate medical attention if you experience serious adverse effects, which may include muscle pain or muscle weakness.

Affected products

Brand

Product Name

Market Authorization

Dosage Form

Strength

Lot

JAMP ATORVASTATIN CALCIUM

JAMP ATORVASTATIN CALCIUM 10 mg

DIN 02504197

Tablet

ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG

D10776B

JAMP ATORVASTATIN CALCIUM

JAMP ATORVASTATIN CALCIUM 40 mg

DIN 02504219

Tablet

ATORVASTATIN (ATORVASTATIN CALCIUM) 40 MG

D10776B

Issue

Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.

Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.

Product from the affected lot was sold to pharmacies between May 2022 and August 2022.

Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side.

Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.

Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).

The Department is monitoring the company's recall and will inform the public if any new health risks are identified.

What you should do

  • Check your bottle of Jamp-Atorvastatin Calcium, 10 mg tablets to make sure it contains 10 mg tablets and not 40 mg tablets. 10 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "10" marked on one side and "AT" marked on the other. 40 mg atorvastatin calcium tablets are white to off-white, oval shaped, film-coated tablets, with "40" marked on one side and "AT" marked on the other.
  • If you are unsure, contact your pharmacist to check if your bottle of Jamp-Atorvastatin Calcium contains the correct tablets.
  • If you see incorrect tablets, stop taking the medication and contact your pharmacy immediately for a replacement product. Return the affected product to your pharmacy for proper disposal.
  • Seek medical attention immediately if you experience any serious adverse effects from atorvastatin calcium which may include muscle pain or muscle weakness.
  • Contact Jamp Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at serviceclient@jamppharma.com, if you have questions about this recall.
  • Report any health product adverse events or complaints to Health Canada.

Additional information

Previous recalls or alerts
Background

Depth of recall: Wholesale, Retailers

Details
Original published date: 2022-08-29
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies

JAMP PHARMA CORPORATION

1310 Rue Nobel, Boucherville

Quebec, J4B 5H3

Published by
Health Canada
Audience
General public
Healthcare
Industry
Retail
Recall class
Type I
Identification number
RA-64512
Media and public enquiries

Media Enquiries
Health Canada
613-957-2983
media@hc-sc.gc.ca

Public Enquiries
613-957-2991
1-866-225-0709